Lancet Neurology

Article	Citations
The East Asian Parkinson Disease Genomics Consortium	4946
Implications of the KIWE trial for low-income and lower-middle-income countries	789
Multidisciplinary care for amyotrophic lateral sclerosis	770
Dementia diagnosis in the anti-amyloid era	750
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	669
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	564
Correction to Lancet Neurol 2024; 23: 168–77	469
Correction to Lancet Neurol 2022; 21: 42–52	435
The predictive value and clinical use of the neurological pupillary index – Authors' reply	415
Correction to Lancet Neurol 2021; 20: 448–59	415
Pseudomedicine for sports concussions in the USA	395
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	394
Traumatic brain injury research: homogenising heterogeneity	367
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	350
New therapies for Pompe disease: are we closer to a cure?	350
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	329
RAB32 mutation in Parkinson's disease	315
Increasing diversity in dementia research	313
Management of atherosclerotic extracranial carotid artery stenosis	302
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	292
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	272
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	258
Lessons and future directions for GBA1-targeting therapies	240
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	226
Global burden of stroke: dynamic estimates to inform action	217

Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	215
Anti-CD19 CAR T cells for refractory myasthenia gravis	213
A biological classification of Huntington's disease: the Integrated Staging System	205
The relevance of social and commercial determinants for neurological health	203
A chilly tale of dementia	192
Trials in intracerebral haemorrhage: a path to success?	190
A study in healing the wounds of trauma	186
Epilepsy syndromes: an essential piece of the puzzle	166
Beyond the modular brain	166
Elia M Pestana Knight	164
Delving into the human mind	162
Albert Kwaku Akpalu	159
A blood test for Alzheimer's disease: a step forward	156
Considering the neurological health needs of LGBTQIA people	154
Safe laboratory management of prions and proteopathic seeds	154
Diana Cejas	153
Gene therapy for X-linked myotubular myopathy: the challenges	150
The prescription of valproate: risk of harm	147
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	147
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	146
Correction to Lancet Neurol 2022; 21: 284–94	143
Correction to Lancet Neurol 2023; 22: 812–25	138
Amyotrophic lateral sclerosis from genotoxins alone?	133
A nasal CGRP receptor antagonist for acute migraine therapy	128
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	127
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	126
Surrogate endpoints for progressive multifocal leukoencephalopathy	124
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	124
Development of treatments for Down syndrome	123
Parkinson's disease is a recognisable and useful diagnostic entity	123
Aspiring to restore arm and hand function after stroke	121
A sensitive portrayal of a controversial condition	119
From stroke awareness to stroke action awareness	116
Movement disorders research in 2021: cracking the paradigm	108
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	107
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	107
Better buildings for elderly people to thrive	106
New results for risdiplam in spinal muscular atrophy	106
Expansion of stenting indications in the USA	105
Correction to Lancet Neurol 2021; 20: 687–89	101
Neurological infections in 2023: surveillance and prevention	100
Responsible innovation in neurology	98
The International Brain Initiative: enabling collaborative science	98
Jessica Ailani	98
Brain health in the Philippines	97
Multiple sclerosis in 2022: old players, new insights	95
Correction to Lancet Neurol 2022; 21: 620–31	95
Correction to Lancet Neurol 2024; 23: 110–22	95
Detection of ionising radiation by the CNS: a case report	95
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	93

The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	93
Changing multiple-sclerosis-induced thoughts and behaviours	92
Supporting young carers across neurological disorders	91
Learning to be an adult with a disability	89
Major advances in Parkinson's disease over the past two decades and future research directions	89
A proposal for equity neuroscience	88
Functional or hysterical?	87
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial	83
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	82
Rethinking AI trials in brain health	82
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	79
Spontaneous intracranial hypotension: searching for the CSF leak	78
α-synuclein seed amplification and its uses in Parkinson's disease	78
Cognitive function in people with functional seizures	77
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	77
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	77
Bastiaan Bloem: power against Parkinson's disease	76
Encephalitis awareness: our ambitious global endeavour	76
Sleeping matters	76
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	76
Brains are neither pink nor blue but fifty shades of grey matter	75
Eugenia Martínez	74
Living with dementia: seeing the world and adapting to it	74
Headache research in 2023: advancing therapy and technology	73
Correction to Lancet Neurol 2024; 23: 961–62	72
Pragmatic solutions for the global burden of stroke	71
ELEVATEd hope for patients after migraine treatment failure	71
Monitoring brainwaves while gallery visitors view artworks	71
A call for optimal oral care in patients with ALS	68
Andrea Schneider	68
Highlights in traumatic brain injury research in 2024	68
Improving thrombolysis efficiency for acute ischaemic stroke	67
Detection of awareness after brain injury: time for change	66
Epilepsy research in 2022: clinical advances	66
Neuroprotection in acute ischaemic stroke: reasons for optimism?	66
Expanding the spectrum of type 1 IFN neuroinflammation	65
The global challenge of hypertension	64
Siddharth Srivastava	63
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	63
Thrombolysis before endovascular treatment of tandem lesions	62
Consciousness contextualised	62
Targeting auto-antibodies for CIDP: hope and questions	62
Neurorehabilitation as a cornerstone of recovery	61
Your After-Visit Summary—May 29, 2042	60
Correction to Lancet Neurol 2024; 23: 344–81	59
Blocking inhibitors of axon growth after spinal cord injury	59
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	58
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	56
Diagnosis and treatment of orthostatic hypotension	56
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	56
The AfrAbia+plus Parkinson's Disease Genomic Consortium	56
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	56
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	54
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	54
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	54
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	53
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	52
The cultural history of dementia	50
The torment of needing to know for sure	50
Biomedical research must change as the climate does	48
Geoffrey Manley: TBI guy	48
Charles Sherrington's apparatus	47
The bases of remembrance	45
Major advances in sleep neurology: 2002–22	44
Neurosurgical lesioning for Tourette syndrome – Authors' reply	44
Thank you to The Lancet Neurology's peer reviewers in 2023	43
A brain design for life	43
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	40
Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	40
Angela Dos Santos	40
Early atrial fibrillation rhythm control after stroke	40
Sleep research in 2023: beyond the bare necessities	40
Changing the landscape of neurological education	40
Carlayne Jackson: leading the American Academy of Neurology	40
Laquinimod, Huntington's disease, and disease modification	40
Therapies for myasthenia gravis: FcRn inhibition and beyond	40
Advances in amyotrophic lateral sclerosis research in 2022	39
Further support for rituximab in relapsing multiple sclerosis	39
A decisive year for the neurological community	39
Correction to Lancet Neurol 2021; 20: 1012–16	39

Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	39
Correction to Lancet Neurol 2024; 23: 465–76	39
Frailty and outcome after traumatic brain injury	39
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	38
For a dementia diagnosis, clinical acumen must precede biomarkers	37
No area of stroke research should be left behind	37
NfL is ready for translation into paediatrics	36
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	36
The complex pathway between amyloid β and cognition: implications for therapy	35
Digital mobility measures to predict Parkinson's disease	35
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	35
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	35
Over a decade of MR-guided focused ultrasound	35
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	34
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	33
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	33
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	33
Globally advancing neurological education in headache	32
Teshamae Monteith	32
Helping to bring the crisis home	32
Improving epilepsy diagnosis across the lifespan: approaches and innovations	32
Friston's theory of everything	31
Correction to Lancet Neurol 2021; 20: 739–52	31
Correction to Lancet Neurol 2023; 22: 209–17	31
Sleep matters in anti-LGI1 encephalitis	31
Correction to Lancet Neurol 2021; 20: 615–26	31
Maria Trojano: advocate for real-world multiple sclerosis studies	30
Revisiting levodopa for advanced Parkinson's disease	30
Nanna Brix Finnerup: integrity and openness to alternatives	30
Neuroscience research in 2024: advances in blood biomarkers and brain omics	30
RAB32 mutation in Parkinson's disease	30
Acute-onset axonal neuropathy following infection in children with biallelic RCC1 variants: a case series	29
Neuroscience in the 21st century: circuits, computation, and behaviour	28
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	28
Abandon the NAC in α-synuclein	28
Video games for people with neurological disorders	28
Correction to Lancet Neurol 2018; 17: 954–76	26
The prescription of valproate: risk of harm	26
Correction to Lancet Neurol 2024; 23: 344–81	26
Blue as an orange	26
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	25
Global burden of meningitis and implications for strategy	25
Heart health meets cognitive health: evidence on the role of blood pressure	25
Nitrous oxide and its neurological harms	25
Advances in diagnosis, classification, and management of pain in Parkinson's disease	25
Time to get serious about the Global Action Plan on dementia	25
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	24
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	24
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	24
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	24
CGRP-targeted drugs for migraine: still many uncertainties	24
Amyotrophic lateral sclerosis: a lesson in translation	23
Dancing with paper	23
Treatment of acute subdural haematoma – Authors' reply	23
Lightning progress in child neurology in the past 20 years	22
Vittorio Marchi's staining	22
With thanks to our peer reviewers in 2022	21
Treatment of asymptomatic carotid stenosis in SPACE-2	21
Addressing neurological burden in the Americas	21
Cerebral amyloid angiopathy criteria: the next generation	21
Fetal exposure to antiseizure medications: reassurance and concerns	20
Carpal tunnel syndrome: updated evidence and new questions	20
The hidden unity of the mind	20
Transforming amyotrophic lateral sclerosis into a liveable disease	20
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	20
Correction to Lancet Neurol 2021; 20: 703–04	20
Differential diagnosis of suspected multiple sclerosis: global health considerations	20
Innovation in the prevention of neurological diseases	20
A neurotransmitter with a fascinating story	19
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	19
A disease-specific therapy in facioscapulohumeral muscular dystrophy	19
Carotid revascularisation for carotid stenosis	19
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	18
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	18
Neurology cannot be embedded in non-communicable disease agendas	18
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	18
CGRP blockade and cluster headache: another step forward	18
Time to end the stigma of epilepsy	18
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	18
Antibiotic neuromuscular junction myasthenic mimetics	17
Chronic effects of inflammation on tauopathies	17
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	17
Turin as a neuroscience cradle	17
The neuropsychiatry of Parkinson's disease: advances and challenges	17
Cerebral cavernous malformations: to operate or not?	17
A genetic basis for the severity of multiple sclerosis	17
Alzheimer's disease: a history revisited	16
Kathleen Friel	16
Expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study	16
Rigmor Højland Jensen: the headache warrior	16
Limping into oblivion	16
A deep scream into the future	16
Changing views of disability	16
Dealing with the reproducibility crisis in neuroscience from the grassroots	16
Correction to Lancet Neurol 2023; 22: 1089–91	15